Lexaria Bioscience Corp. submitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its upcoming clinical trial, HYPER-H23-1.

A recent study has shown that NTLA-2002, an experimental gene editing treatment for hereditary angioedema (HAE), significantly reduced the frequency of swelling attacks in patients.

Bio-Thera Solutions has initiated a Phase IA/IIA clinical trial for BAT6026, a monoclonal antibody designed to target OX40.

Therapeutic company Theradaptive has received approval from the U.S. FDA to initiate a global Phase I/II study for its spinal fusion product, OsteoAdapt SP.

Sirius Therapeutics has initiated a Phase 1 clinical trial for SRSD107, an innovative siRNA treatment aimed at preventing and managing thromboembolic disorders by targeting coagulation Factor XI (FXI).

The first individual has been administered TH104 in a Phase 1 clinical trial, focusing on the drug's safety, tolerability, and absolute bioavailability.

Sangamo Therapeutics has reported positive interim results from its Phase 1/2 STAAR clinical trial for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease.

ProLynx Inc. initiated a Phase I/II clinical study involving PLX038, a PEGylated form of SN-38, for treating primary central nervous system (CNS) tumors with MYC or MYCN gene amplifications.

ProfoundBio has launched the Phase 1/2 clinical trial for PRO1107, marking a significant step in their mission to enhance patient outcomes.

Rani Therapeutics Holdings, Inc. reported encouraging topline results from its Phase 1 clinical trial of RT-111, a RaniPill® capsule containing an ustekinumab biosimilar (CT-P43).

This study is focused on evaluating the safety and effectiveness of TAC101-CLDN18.2, an advanced cell therapy that utilizes genetically modified autologous T cells.

In the early 20th century, Alois Alzheimer identified neuroinflammation as a factor in the disease now named after him, noting the presence of microglia cells in his initial sketches.